insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test
AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.
Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care
Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.